# Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer

> **NCT04322617** · PHASE2,PHASE3 · RECRUITING · sponsor: **Hunan Province Tumor Hospital** · enrollment: 1200 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Anlotinib plus the same Immune Checkpoint Inhibitors.
- **DRUG:** Anlotinib plus the new Immune Checkpoint Inhibitors.
- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT04322617
- **Lead sponsor:** Hunan Province Tumor Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-03-24
- **Primary completion:** 2028-03-24
- **Final completion:** 2029-03-24
- **Target enrollment:** 1200 (ESTIMATED)
- **Last updated:** 2024-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04322617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04322617, "Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04322617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*